Transplant Research Institute, James D. Eason Transplant Institute, Department of Surgery, School of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, United States.
Division of Nephrology and the Center for Immunity, Inflammation and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, United States.
Front Immunol. 2020 Jun 23;11:1278. doi: 10.3389/fimmu.2020.01278. eCollection 2020.
Dendritic cells (DCs) are central in regulating immune responses of kidney ischemia-reperfusion injury (IRI), and strategies to alter DC function may provide new therapeutic opportunities. Sphingosine 1-phosphate (S1P) modulates immunity through binding to its receptors (S1P1-5), and protection from kidney IRI occurs in mice treated with S1PR agonist, FTY720 (FTY). We tested if propagation of DCs with FTY could be used as cellular therapy to limit the off-target effects associated with systemic FTY administration in kidney IRI. DCs have the ability of regulate innate and adaptive responses and we posited that treatment of DC with FTY may underlie improvements in kidney IRI. Herein, it was observed that treatment of bone marrow derived dendritic cells (BMDCs) with FTY induced mitochondrial biogenesis, FTY-treated BMDCs (FTY-DCs) showed significantly higher oxygen consumption rate and ATP production compared to vehicle treated BMDCs (Veh-DCs). Adoptive transfer of FTY-DCs to mice 24 h before or 4 h after IRI significantly protected the kidneys from injury compared to mice treated with Veh-DCs. Additionally, allogeneic adoptive transfer of C57BL/6J FTY-DCs into BALB/c mice equally protected the kidneys from IRI. FTY-DCs propagated from -deficient DCs derived from mice as well as blunting mitochondrial oxidation in wildtype (WT) FTY-DCs prior to transfer abrogated the protection observed by FTY-DCs. We queried if DC mitochondrial content alters kidney responses after IRI, a novel but little studied phenomenon shown to be integral to regulation of the immune response. Transfer of mitochondria rich FTY-DCs protects kidneys from IRI as transferred FTY-DCs donated their mitochondria to recipient splenocytes (i.e., macrophages) and prior splenectomy abrogated this protection. Adoptive transfer of FTY-DCs either prior to or after ischemic injury protects kidneys from IRI demonstrating a potent role for donor DC-mitochondria in FTY's efficacy. This is the first evidence, to our knowledge, that DCs have the potential to protect against kidney injury by donating mitochondria to splenic macrophages to alter their bioenergetics thus making them anti-inflammatory. In conclusion, the results support that FTY720-induction of the regulatory DC phenotype could have therapeutic relevance that can be preventively infused to reduce acute kidney injury.
树突状细胞 (DCs) 在调节肾脏缺血再灌注损伤 (IRI) 的免疫反应中起着核心作用,改变 DC 功能的策略可能为新的治疗机会提供了可能。鞘氨醇 1-磷酸 (S1P) 通过与其受体 (S1P1-5) 结合来调节免疫,用 S1PR 激动剂 FTY720 (FTY) 治疗可防止发生肾脏 IRI。我们测试了用 FTY 增殖 DC 是否可以用作细胞疗法来限制与肾脏 IRI 中全身 FTY 给药相关的脱靶效应。DC 具有调节先天和适应性反应的能力,我们假设用 FTY 治疗 DC 可能是改善肾脏 IRI 的基础。在此,观察到用 FTY 处理骨髓来源的树突状细胞 (BMDCs) 可诱导线粒体生物发生,与用载体处理的 BMDCs (Veh-DCs) 相比,FTY 处理的 BMDCs (FTY-DCs) 显示出明显更高的耗氧量和 ATP 产生。在 IRI 前 24 小时或后 4 小时将 FTY-DC 过继转移到小鼠体内,与用 Veh-DC 处理的小鼠相比,可显著保护肾脏免受损伤。此外,将 C57BL/6J 同种异体 FTY-DC 过继转移到 BALB/c 小鼠中,同样可防止 IRI 损伤肾脏。从 基因缺陷小鼠衍生的 DC 中增殖的 FTY-DC 以及在转移前减弱野生型 (WT) FTY-DC 中线粒体氧化作用,均可消除由 FTY-DC 观察到的保护作用。我们询问了 DC 线粒体含量是否会改变 IRI 后的肾脏反应,这是一种新颖但研究甚少的现象,被证明是调节免疫反应的重要组成部分。富含线粒体的 FTY-DC 的转移可保护肾脏免受 IRI,因为转移的 FTY-DC 将其线粒体捐赠给受体脾细胞(即巨噬细胞),而脾切除术则消除了这种保护作用。在缺血性损伤之前或之后过继转移 FTY-DC 可保护肾脏免受 IRI,这表明供体 DC-线粒体在 FTY 的疗效中具有潜在作用。这是第一个证据,据我们所知,DC 通过将线粒体捐赠给脾巨噬细胞来改变其生物能量,从而使它们具有抗炎作用,从而有可能通过捐赠线粒体来保护肾脏免受损伤。总之,这些结果支持这样一种观点,即 FTY720 诱导的调节性 DC 表型可能具有治疗相关性,可以预防性输注以减少急性肾损伤。